| 1.495 -0.005 (-0.33%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.94  |
1-year : | 2.1 |
| Resists | First : | 1.66 |
Second : | 1.79 |
| Pivot price | 1.58 |
|||
| Supports | First : | 1.44 |
Second : | 1.19 |
| MAs | MA(5) : | 1.52 |
MA(20) : | 1.61 |
| MA(100) : | 1.46  |
MA(250) : | 2.77 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 17.4 |
D(3) : | 22.6 |
| RSI | RSI(14): 38.4 |
|||
| 52-week | High : | 5.49 | Low : | 1.15 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ PULM ] has closed above bottom band by 17.2%. Bollinger Bands are 29.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.55 - 1.56 | 1.56 - 1.57 |
| Low: | 1.41 - 1.43 | 1.43 - 1.44 |
| Close: | 1.48 - 1.49 | 1.49 - 1.51 |
Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.
Tue, 18 Aug 2026
Pulmatrix Inc (NASDAQ: PULM) Share Price, PULM Stock News, PULM Share Price & Updates - Kalkine
Thu, 13 Aug 2026
Pulmatrix posts Q2 2026 net loss $1.04M, cash $2.2M; files Form S-4 for Eos merger - TradingView
Thu, 13 Aug 2026
PULM: Future operations hinge on the Eos merger; cash runway is limited without additional funding - TradingView
Thu, 13 Aug 2026
Pulmatrix, Inc. Q2 2026: Net loss $1.05M, EPS $(0.29) — 10-Q Summary - TradingView
Thu, 13 Aug 2026
Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger - PR Newswire
Fri, 07 Aug 2026
Pulmatrix Inc (PULM) Stock News Today - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 9 (%) |
| Shares Short | 27 (K) |
| Shares Short P.Month | 10 (K) |
| EPS | -1.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -46 % |
| Return on Equity (ttm) | -84.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.02 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.22 |
| PEG Ratio | 0 |
| Price to Book value | 2.07 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|